Skip NavigationSkip to Content
Return Return to Search Results

Dosimetry and first human experience with (89)Zr-panitumumab

  1. Author:
    Lindenberg, Liza
    Adler, Stephen
    Turkbey, Ismail B
    Mertan, Francesca
    Ton, Anita
    Do, Khanh
    Kummar, Shivaani
    Gonzalez, Esther Mena
    Bhattacharyya, Sibaprasad
    Jacobs, Paula M
    Choyke, Peter

  2. Author Address

    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of HealthBethesda, MD, USA., Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer ResearchFrederick, Maryland 21702, USA., Dana-Farber Cancer InstituteBoston, MA, USA., Stanford University School of MedicinePalo Alto, CA, USA., Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug AdministrationSilver Spring, MD, USA., Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of HealthBethesda, MD, USA.,
    1. Year: 2017
    2. Date: Sep 01
  2. Journal: American Journal of Nuclear Medicine and Molecular Imaging
    1. 7
    2. 4
    3. Pages: 195-203
  4. Type of Article: Article
  5. Article Number: 195-203
  1. Abstract:

    (89)Zr-panitumumab is a novel immuno-PET radiotracer. A fully humanized IgG2 antibody, panitumumab binds with high affinity to the extracellular ligand binding domain of EGFR. Immuno-PET with radiolabeled panitumumab is a non-invasive method that could characterize EGFR expression in tumors and metastatic lesions. It might also assist in selecting patients likely to benefit from targeted therapy as well as monitor response and drug biodistribution for dosing guidance. Our objective was to calculate the maximum dosing for effective imaging with minimal radiation exposure in a small subset. Three patients with metastatic colon cancer were injected with approximately 1 mCi (37 MBq) of (89)Zr-panitumumab IV. Whole body static images were then obtained at 2-6 hours, 1-3 days and 5-7 days post injection. Whole organ contours were applied to the liver, kidneys, spleen, stomach, lungs, bone, gut, heart, bladder and psoas muscle. From these contours, time activity curves were derived and used to calculate mean resident times which were used as input into OLINDA 1.1 software for dosimetry estimates. The whole body effective dose was estimated between 0.264 mSv/MBq (0.97 rem/mCi) and 0.330 mSv/MBq (1.22 rem/mCi). The organ which had the highest dose was the liver which OLINDA estimated between 1.9 mGy/MBq (7.2 rad/mCi) and 2.5 mGy/MBq (9 rad/mCi). The effective dose is within range of extrapolated estimates from mice studies. (89)Zr-panitumumab appears safe and dosimetry estimates are reasonable for clinical imaging.

    See More

  1. Keywords:

External Sources

  1. PMID: 28913158
  2. PMCID: PMC5596322

Library Notes

  1. Fiscal Year: FY2016-2017
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel